Canine VEGF / VEGFA Protein

VEGFA, VEGF

100ug (NPP1605) Please inquiry

Catalog Number	P70004-DNAH
Organism Species	Canine
Host	Human Cells
Synonyms	VEGFA, VEGF
Molecular Weight	The recombinant canine VEGFA comprises 164 amino acids and has a predicted molecular mass of 19.1 kDa. The apparent molecular mass of the protein is approximately 23 kDa in SDS-PAGE under reducing conditions due to glycosylation.
predicted N	Ala 27
SDS-PAGE
Purity	> 95 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the canine VEGFA(NP_001103972.1) (Met1-Arg190) was expressed.
Bio-activity	Immobilized canine VEGFA at 10 μg/ml (100 μl/well) can bind human VEGFR2-Fc (P10012-H02H), The EC₅₀ of human VEGFR2-Fc (P10012-H02H) is 33.83-78.95 ng/ml.
Research Area	Cardiovascular \|Angiogenesis \|Growth Factor & Receptor \|Vascular Endothelial Growth Factor (VEGF) & Receptor \|Vascular Endothelial Growth Factor (VEGF)
Formulation	Lyophilized from sterile PBS, pH 7.4. 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.
Reference	Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835. Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97. Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8. Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14. Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193. Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.